Skip to main content

Table 2 COVID-19 data

From: Natalizumab administration in multiple sclerosis patients during active SARS-CoV-2 infection: a case series

Patient

1

2

3

4

5

6

Date of the first positive oropharyngeal/nasopharyngeal swab

12/OCT/20

14/NOV/20

13/JAN/21

15/JAN/21

16/JAN/21

05/FEB/21

Severity of COVID-19

mild

moderate

mild

mild

mild

mild

7-point ordinal scale for grading clinical status of COVID-19

1

3

1

1

2

1

COVID-19 treatments

none

paracetamol, azitromicine, prednisolone

none

none

paracetamol

none

COVID-19 symptoms

none

fever, sore throat, loss of taste, loss of smell

none

none

headache, bone or joint pain, nasal congestion, loss of taste, loss of smell

none

Hospitalization

no

yes

no

no

no

no

Date of NTZ administration during COVID-19

26/NOV/20

02/DEC/20

14/JAN/21

20/JAN/21

27/JAN/21

10/FEB/21

Date of the negative oropharyngeal/nasopharyngeal swab

30/NOV/20

28/DEC/20

28/JAN/21

16/FEB/21

25/FEB/21

08/MAR/21

COVID-19 duration (days)

39

44

15

32

40

31

  1. NTZ natalizumab, COVID-19 Coronavirus Disease 2019